اخبار و اعلانات

 آمار

تعداد نشریات282
تعداد نشریات سازمان80
تعداد شماره‌ها3,262
تعداد مقالات36,058
تعداد مشاهده مقاله55,187,657
تعداد دریافت فایل اصل مقاله94,186,170
Pakhomov, S. P, Orlova, V. S, Verzilina, I. N, Sukhih, N. V, Nagorniy, A. V, Matrosova, A. V. (1400). Risk Factors and Methods for Predicting Ovarian Hyperstimulation Syndrome (OHSS) in the in vitro Fertilization. سامانه مدیریت نشریات علمی, 76(5), 1461-1468. doi: 10.22092/ari.2021.356170.1796
S. P Pakhomov; V. S Orlova; I. N Verzilina; N. V Sukhih; A. V Nagorniy; A. V Matrosova. "Risk Factors and Methods for Predicting Ovarian Hyperstimulation Syndrome (OHSS) in the in vitro Fertilization". سامانه مدیریت نشریات علمی, 76, 5, 1400, 1461-1468. doi: 10.22092/ari.2021.356170.1796
Pakhomov, S. P, Orlova, V. S, Verzilina, I. N, Sukhih, N. V, Nagorniy, A. V, Matrosova, A. V. (1400). 'Risk Factors and Methods for Predicting Ovarian Hyperstimulation Syndrome (OHSS) in the in vitro Fertilization', سامانه مدیریت نشریات علمی, 76(5), pp. 1461-1468. doi: 10.22092/ari.2021.356170.1796
Pakhomov, S. P, Orlova, V. S, Verzilina, I. N, Sukhih, N. V, Nagorniy, A. V, Matrosova, A. V. Risk Factors and Methods for Predicting Ovarian Hyperstimulation Syndrome (OHSS) in the in vitro Fertilization. سامانه مدیریت نشریات علمی, 1400; 76(5): 1461-1468. doi: 10.22092/ari.2021.356170.1796

Risk Factors and Methods for Predicting Ovarian Hyperstimulation Syndrome (OHSS) in the in vitro Fertilization

Archives of Razi Institute
مقاله 36، دوره 76، شماره 5، بهمن و اسفند 2021، صفحه 1461-1468    اصل مقاله (488.22 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2021.356170.1796
نویسندگان
S. P Pakhomov* 1؛ V. S Orlova1؛ I. N Verzilina1؛ N. V Sukhih1؛ A. V Nagorniy1؛ A. V Matrosova2
1Belgorod State University, 85 Pobedy St., Belgorod, 308015, Russia
2Belgorod Regional Hospital, 8 Nekrasova St., Belgorod, 308009, Russia
چکیده
Ovarian hyperstimulation syndrome (OHSS) is the most severe and life-threatening complication of assisted reproductive technologies (ART). OHSS is based on an excessive ovarian response to ovarian stimulation; however, the pathogenesis has not been fully understood yet. The most serious complications of OHSS are thromboembolic complications and ovarian torsion. The current study describes the risk factors for the development of ovarian hyperstimulation syndrome and proposes a method for specific prediction of this syndrome. This study was designed to investigate 671 therapeutic cycles in the IVF program during 2009-2018. All patients were divided into two groups. Group one (n=56) included women who developed OHSS during the IVF procedure. Group two (n=615) consisted of women who did not have this complication during the IVF procedure. All the observation and examination outcomes were entered into a specially developed questionnaire, and then into a Microsoft Excel spreadsheet. The data were processed by variable statistics using Statistica 10.0. Analyzing of the recorded data revealed that the rate of OHSS was higher in the group of younger women, aged 30.76±3.67 years, in comparison with those aged 32.78±4.40 years in the group of patients without OHSS (p<0.05). The analysis of the initial phase of the reproductive system has confirmed that the group of patients with OHSS had a higher level of prolactin, 462.84±191.56 mIU/L in comparison with 363.43±187.84 mIU/L, which corresponded to the group of women without OHSS (p<0.05). In our results, 7.15±1.04% of cases with OHSS had obesity, while of the patients from the group without OHSS suffered from it (p<0.05). OHSS is the most severe iatrogenic complication of ART, therefore it is extremely important to consider its risk factors and take timely preventive measures. This study has established a high relationship between the studied risk factors and ovarian hyperstimulation syndrome and proposed a model for predicting this syndrome.
کلیدواژه‌ها
Hyperstimulation Syndrome؛ in Vitro Fertilization؛ Infertility؛ Pregnancy؛ Ovarian
سایر فایل های مرتبط با مقاله
مراجع
  1. Barbieri R. Female infertility. Yen and Jaffe's Reproductive Endocrinology. London: Elsevier; 2019.
  2. Liu F, Jiang Q, Sun X, Huang Y, Zhang Z, Han T, et al. Lipid metabolic disorders and ovarian hyperstimulation syndrome: a retrospective analysis. Front Physiol. 2020;11.
  3. Palomba S, Falbo A, Carrillo L, Villani MT, Orio F, Russo T, et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertil Steril. 2011;96(6):1384-90.
  4. Wallach E, Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril. 1978;30(3):255-68.
  5. Fineschi V, Neri M, Di Donato S, Pomara C, Riezzo I, Turillazzi E. An immunohistochemical study in a fatality due to ovarian hyperstimulation syndrome. Int J Legal Med. 2006;120(5):293-9.
  6. Aboulghar M, Mansour R. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update. 2003;9(3):275-89.
  7. Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 2008;14(4):321-33.
  8. Dey AK, Dubey A, Mittal K, Kale S. Spontaneous ovarian hyperstimulation syndrome–understanding the dilemma. Gynecol Endocrinol. 2015;31(8):587-9.
  9. Kasum M. New insights in mechanisms for development of ovarian hyperstimulation syndrome. Coll. 2010;34(3):1139-43.
  10. Vloeberghs V, Peeraer K, Pexsters A, D'Hooghe T. Ovarian hyperstimulation syndrome and complications of ART. Best Pract Res Clin Obstet Gynaecol. 2009;23(5):691-709.
  11. Al-Ramahi M, Leader A, Claman P, Spence J. A novel approach to the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum Reprod. 1997;12(12):2614-6.
  12. Galway A, Lapolt P, Tsafriri A, Dargan C, Boime I, Hsueh AJ. Recombinant follicle-stimulating hormone induces ovulation and tissue plasminogen activator expression in hypophysectomized rats. Endocrinology. 1990;127(6):3023-8.
  13. Endo T, Honnma H, Hayashi T, Chida M, Yamazaki K, Kitajima Y, et al. Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Hum Reprod. 2002;17(10):2548-51.
  14. Cole LA. The hCG assay or pregnancy test. CCLM. 2012;50(4):617-30.
  15. Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 1988;159(1):210-5.
  16. Medicine PCotASfR. Ovarian hyperstimulation syndrome. Fertil Steril. 2008;90(5):S188-S93.
  17. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010;94(2):389-400.
  18. Lee T-H, Liu C-H, Huang C-C, Wu Y-L, Shih Y-T, Ho H-N, et al. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod. 2008;23(1):160-7.
  19. Budev MM, Arroliga AC, Falcone T. Ovarian hyperstimulation syndrome. Crit Care Med. 2005;33(10):S301-S6.
  20. Blankstein J, Shalev J, Saadon T, Kukia EE, Rabinovici J, Pariente C, et al. Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertil Steril. 1987;47(4):597-602.
  21. Sahu B, Ozturk O, Ranierri M, Serhal P. Comparison of oocyte quality and intracytoplasmic sperm injection outcome in women with isolated polycystic ovaries or polycystic ovarian syndrome. Arch Gynecol Obstet. 2008;277(3):239-44.
  22. Chen Z-J, Shi Y, Sun Y, Zhang B, Liang X, Cao Y, et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med. 2016;375:523-33.
  23. Ocal P, Sahmay S, Cetin M, Irez T, Guralp O, Cepni I. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist ReprodGenet. 2011;28(12):1197-203.
  24. Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2012;(2).
  25. Youssef MA, Abou‐Setta AM, Lam WS. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev. 2016;(4).
  26. van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015;(7).
  27. Luke B, Brown MB, Morbeck DE, Hudson SB, Coddington III CC, Stern JE. Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome. Fertiland steril. 2010;94(4):1399-404.
  28. Check J. Ovulation disorders: part I anovulation associated with estrogen deficiency. Clin Exp Obstet Gynecol. 2007;34(1):5-8.
  29. Health and fertility in World Health Organization group 2 anovulatory women. Hum Reprod Update. 2012;18(5):586-99.
  30. Kemmann E, Jones JR. Hyperprolactinemia and primary amenorrhea. Obstet Gynecol. 1979;54(6):692-4.
  31. Lindh A, Carlström K, Eklund J, Wilking N. Serum steroids and prolactin during and after major surgical trauma. Acta Anaesthesiol Scand. 1992;36(2):119-24.
  32. Chiocca E, Dati E, Baroncelli GI, Mora S, Parrini D, Erba P, et al. Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height. Neuroendocrinology. 2009;89(4):441-7.
  33. Iijima M, Kisu I, Shiraishi T, Irie R, Hirao N. A Rare Urothelial Malignant Transformation in a Mature Cystic Teratoma of the Ovary. Cureus. 2021;13(8).
  34. Lizcano F, Guzmán G. Estrogen deficiency and the origin of obesity during menopause. Biomed Res Int. 2014;2014.
  35. Vikan T, Schirmer H, Njølstad I, Svartberg J. Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. Eur J Endocrinol. 2010;162(4):747.
  36. Madill JJ, Mullen NB, Harrison BP. Ovarian
    hyperstimulation syndrome: a potentially fatal complication of early pregnancy. J Emerg Med. 2008;35(3):283-6.
  1. Aboulghar M, Evers J, Al-Inany H. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod. 2002;17(12):3027-32.
  2. Ryley N, Forman R, Barlow D, Fleming K, Trowell J. Liver abnormality in ovarian hyperstimulation syndrome. Hum Reprod. 1990;5(8):938-43.
آمار
تعداد مشاهده مقاله: 2,629
تعداد دریافت فایل اصل مقاله: 3,139


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب